Correlation Between Anebulo Pharmaceuticals and Lyell Immunopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Anebulo Pharmaceuticals and Lyell Immunopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Anebulo Pharmaceuticals and Lyell Immunopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Anebulo Pharmaceuticals and Lyell Immunopharma, you can compare the effects of market volatilities on Anebulo Pharmaceuticals and Lyell Immunopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Anebulo Pharmaceuticals with a short position of Lyell Immunopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Anebulo Pharmaceuticals and Lyell Immunopharma.

Diversification Opportunities for Anebulo Pharmaceuticals and Lyell Immunopharma

0.72
  Correlation Coefficient

Poor diversification

The 3 months correlation between Anebulo and Lyell is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Anebulo Pharmaceuticals and Lyell Immunopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyell Immunopharma and Anebulo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Anebulo Pharmaceuticals are associated (or correlated) with Lyell Immunopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyell Immunopharma has no effect on the direction of Anebulo Pharmaceuticals i.e., Anebulo Pharmaceuticals and Lyell Immunopharma go up and down completely randomly.

Pair Corralation between Anebulo Pharmaceuticals and Lyell Immunopharma

Given the investment horizon of 90 days Anebulo Pharmaceuticals is expected to generate 0.88 times more return on investment than Lyell Immunopharma. However, Anebulo Pharmaceuticals is 1.13 times less risky than Lyell Immunopharma. It trades about -0.19 of its potential returns per unit of risk. Lyell Immunopharma is currently generating about -0.18 per unit of risk. If you would invest  308.00  in Anebulo Pharmaceuticals on September 20, 2024 and sell it today you would lose (177.00) from holding Anebulo Pharmaceuticals or give up 57.47% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Anebulo Pharmaceuticals  vs.  Lyell Immunopharma

 Performance 
       Timeline  
Anebulo Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Anebulo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Lyell Immunopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lyell Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Anebulo Pharmaceuticals and Lyell Immunopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Anebulo Pharmaceuticals and Lyell Immunopharma

The main advantage of trading using opposite Anebulo Pharmaceuticals and Lyell Immunopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Anebulo Pharmaceuticals position performs unexpectedly, Lyell Immunopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyell Immunopharma will offset losses from the drop in Lyell Immunopharma's long position.
The idea behind Anebulo Pharmaceuticals and Lyell Immunopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories